Pigmentation treatment options list: what actually works
TL;DR:
- Effective hyperpigmentation management depends on daily broad-spectrum sun protection and a personalized, multimodal treatment plan. Topical agents, chemical peels, laser therapies, microneedling, and systemic treatments work best when combined with consistent photoprotection and tailored to individual skin types and conditions. Long-term, durable results require patience, ongoing maintenance, and expert guidance from dermatologists or clinicians.
Effective management of hyperpigmentation relies on one non-negotiable foundation, daily broad-spectrum photoprotection, combined with a personalised, multimodal plan drawn from four main treatment categories. International dermatology consensus confirms that no single therapy works in isolation, and that tailoring options to your specific disorder subtype, skin type, and lifestyle gives the most durable results. There is no guaranteed permanent cure for most pigment conditions, but evidence consistently shows that structured, evidence-backed protocols produce meaningful, lasting improvement.
The main treatment categories in any pigmentation treatment options list are:
- Topical agents (hydroquinone, azelaic acid, retinoids, vitamin C, kojic acid, cysteamine, niacinamide, tranexamic acid, thiamidol/arbutin)
- Superficial to medium-depth chemical peels (glycolic, salicylic, trichloroacetic acid)
- Laser and light therapies (Q-switched Nd:YAG, picosecond, fractional resurfacing, IPL)
- Microneedling and microdermabrasion
- Oral and adjuvant systemic therapies (oral tranexamic acid, antioxidant supplements)
- Emerging and research-stage formats (nanocarriers, liposomes, PRP, polynucleotides)
Photoprotection underpins every category above. Without consistent SPF use, even the most sophisticated procedural plan produces limited or temporary results.
Table of Contents
- What are the best topical treatments for pigmentation?
- Which procedural treatments work for skin discolouration?
- Oral and adjuvant therapies: when are systemic options considered?
- What emerging therapies are on the horizon for pigmentation?
- How do you match a treatment to your skin type and condition?
- Realistic treatment plans for common pigmentation conditions
- When should you see a dermatologist or skin specialist?
- Key takeaways
- The case for patience over perfection in pigmentation care
- How Them-ethod can support your pigmentation plan
- Useful sources and further reading
What are the best topical treatments for pigmentation?
Topical therapy is first-line for most hyperpigmentation disorders, including post-inflammatory hyperpigmentation (PIH), melasma, and solar lentigos. The agents work through four main mechanisms: tyrosinase inhibition (blocking melanin synthesis at source), melanosome transfer inhibition, accelerated cell turnover and exfoliation, and antioxidant or anti-inflammatory action. Most effective protocols combine agents from more than one mechanism group.
The main active ingredients
Hydroquinone remains the long-standing topical gold standard for tyrosinase inhibition. In the UK, concentrations above 2% are prescription-only; over-the-counter products are limited to cosmetic-grade formulations. Clinical use is typically time-limited to 3–6 months to reduce the risk of ochronosis (paradoxical darkening with prolonged use). It is contraindicated in pregnancy and breastfeeding.
Azelaic acid (10–20%) inhibits tyrosinase and has an anti-inflammatory action that makes it particularly well suited to PIH and rosacea-associated pigmentation. The 20% prescription strength (available as Skinoren in the UK) is considered safe in pregnancy, making it one of the few clinically supported options for that group.
Retinoids (tretinoin 0.025–0.1%, adapalene 0.1–0.3%) accelerate epidermal turnover, dispersing melanin granules and enhancing penetration of co-applied actives. Tretinoin is prescription-only in the UK; adapalene 0.1% is available over the counter. Both require a gradual introduction to minimise irritation, and neither is recommended in pregnancy.
Vitamin C (L-ascorbic acid, typically 10–20%) acts as an antioxidant, interrupting melanin synthesis and providing photoprotection synergy when layered under SPF. Stability varies significantly between formulations; look for pH-adjusted, air-limited packaging.
Kojic acid (1–4%) inhibits tyrosinase and is widely available in OTC serums and creams. It can cause contact sensitisation in some people, so patch-testing is advisable before full-face use.
Cysteamine (5%) is a newer tyrosinase inhibitor with a growing evidence base and a favourable safety profile compared with hydroquinone. It is available in several OTC formulations in the UK.
Niacinamide (2–10%) works primarily by inhibiting melanosome transfer from melanocytes to keratinocytes rather than blocking synthesis directly. It is well tolerated across all skin types, non-irritating, and widely available OTC, making it an excellent maintenance and combination ingredient.
Tranexamic acid (2–5% topical) inhibits the interaction between keratinocytes and melanocytes, reducing UV-stimulated pigmentation. It is available in OTC serums and is particularly useful in melasma maintenance.
Thiamidol and alpha-arbutin are tyrosinase inhibitors with emerging clinical data supporting efficacy comparable to hydroquinone in some studies, with a more favourable tolerability profile. Both are available in OTC formulations.
| Active ingredient | Mechanism | UK availability | Typical onset | Key cautions |
|---|---|---|---|---|
| Hydroquinone (2–4%) | Tyrosinase inhibition | Prescription (>2%) | 4–8 weeks | Time-limited use; avoid in pregnancy |
| Azelaic acid (10–20%) | Tyrosinase inhibition + anti-inflammatory | OTC (10%); Rx (20%) | 4–12 weeks | Generally safe in pregnancy at 20% Rx |
| Tretinoin (0.025–0.1%) | Cell turnover acceleration | Prescription only | 8–16 weeks | Avoid in pregnancy; start low |
| Adapalene (0.1%) | Cell turnover acceleration | OTC (0.1%) | 8–16 weeks | Avoid in pregnancy |
| Vitamin C (10–20%) | Antioxidant; melanin synthesis inhibition | OTC | 6–12 weeks | Formulation stability critical |
| Kojic acid (1–4%) | Tyrosinase inhibition | OTC | 4–8 weeks | Patch-test; sensitisation risk |
| Cysteamine (5%) | Tyrosinase inhibition | OTC | 8–16 weeks | Avoid contact with eyes |
| Niacinamide (2–10%) | Melanosome transfer inhibition | OTC | 4–8 weeks | Excellent tolerability; all skin types |
| Tranexamic acid (2–5%) | Keratinocyte-melanocyte interaction | OTC | 8–12 weeks | Generally well tolerated |
| Thiamidol / arbutin | Tyrosinase inhibition | OTC | 8–12 weeks | Mild; suitable for sensitive skin |
Research from the Wiley clinical review confirms that hydroquinone’s alternatives, particularly azelaic acid, niacinamide, and thiamidol, offer mechanism diversity and safety advantages that make them preferable for long-term or maintenance use. For readers building a skincare routine for pigmentation, combining a tyrosinase inhibitor with a cell-turnover agent and a daily SPF is the most evidence-supported starting point.
Safety callouts worth noting: steroid-containing combination creams (sometimes sold as “skin-lightening” products) carry significant risks including skin atrophy, telangiectasia, and rebound hyperpigmentation. The British Association of Dermatologists advises against unsupervised use of such products. Always prime the skin with a gentle routine for at least two weeks before starting any active treatment, and introduce new actives one at a time.
Which procedural treatments work for skin discolouration?
Procedural options are typically second-line, used when topical therapy alone has not achieved sufficient improvement or when the lesion type (such as a solar lentigo) responds better to a targeted physical intervention. Multimodality management, combining procedural and topical approaches, consistently outperforms monotherapy in clinical evaluations.
Chemical peels
Chemical peels remove superficial layers of the epidermis to accelerate pigment clearance and stimulate renewal. The depth of the peel determines both the efficacy and the recovery time.
- Superficial peels (glycolic acid 20–70%, salicylic acid 20–30%, mandelic acid): minimal downtime (1–3 days of mild flaking), suitable for all Fitzpatrick types with appropriate concentration adjustment, and often used in a series of 4–6 sessions spaced 2–4 weeks apart.
- Medium-depth peels (TCA 15–35%, Jessner’s solution combinations): more pronounced exfoliation, 5–10 days of visible peeling, stronger results for solar lentigos and moderate melasma, but higher PIH risk in Fitzpatrick types IV–VI.
- Indications: solar lentigos, epidermal melasma, PIH (superficial peels), actinic damage.
Laser and light therapies
Laser and light-based devices target melanin selectively, breaking up pigment deposits for clearance by the immune system. The choice of device depends on lesion type, depth, and skin tone.
Q-switched Nd:YAG (1064 nm / 532 nm) is widely used for solar lentigos, café-au-lait macules, and melasma. The 1064 nm wavelength is safer for darker skin types (Fitzpatrick IV–VI) because it is less absorbed by epidermal melanin, reducing the risk of PIH. Low-fluence protocols are recommended for higher skin types.
Picosecond lasers (755 nm, 532 nm, 1064 nm) deliver energy in ultra-short pulses, shattering pigment with less thermal damage than nanosecond devices. They are increasingly used for recalcitrant melasma and tattoo-associated pigmentation, with a generally lower PIH risk than Q-switched nanosecond devices.
Fractional resurfacing (ablative: CO2, Er:YAG; non-ablative: 1550 nm, 1927 nm) creates microscopic treatment zones, stimulating collagen remodelling alongside pigment reduction. Ablative fractional lasers carry higher downtime (7–14 days) and PIH risk; non-ablative fractional options are better tolerated in darker skin types.
Intense Pulsed Light (IPL) uses broad-spectrum light to target both melanin and vascular components. It is effective for solar lentigos and diffuse redness in fair skin (Fitzpatrick I–III) but carries a higher risk of burns and PIH in darker skin types and should be used with caution or avoided in Fitzpatrick IV–VI.
Wiley’s clinical review notes that lasers and light-based devices are effective first-line management for visible lentigos in fair skin, but require lower fluence and greater caution in higher Fitzpatrick types to reduce post-treatment inflammation.
Microneedling and microdermabrasion
Microneedling (collagen induction therapy) uses fine needles to create controlled micro-injuries, stimulating collagen production and enhancing the penetration of co-applied topical agents. When combined with topical brightening serums or PRP, it can improve pigment outcomes beyond what either approach achieves alone. Evidence is growing, though protocol consistency across studies varies. The FDA-approved SkinPen is one of the most clinically validated microneedling devices available in the UK.
Microdermabrasion uses fine crystals or a diamond tip to physically exfoliate the epidermis. It is gentler than chemical peels and suitable for superficial pigmentation and skin texture concerns. Results are modest compared with peels or lasers, and multiple sessions are typically needed.
Pro Tip: For Fitzpatrick types IV–VI, always prime the skin with a tyrosinase inhibitor (such as azelaic acid or niacinamide) for at least 4 weeks before any procedural treatment. Patch-testing at a lower energy or concentration is non-negotiable. This significantly reduces the risk of post-procedural PIH.
| Procedure | Typical sessions | Downtime | PIH risk by skin type | Best indications |
|---|---|---|---|---|
| Superficial chemical peel | 4–6 | 1–3 days | Low (I–III); moderate (IV–VI) | PIH, melasma, solar lentigos |
| Medium-depth peel (TCA) | 1–3 | 5–10 days | Moderate (I–III); high (IV–VI) | Solar lentigos, moderate melasma |
| Q-switched Nd:YAG | 3–6 | Minimal | Low at 1064 nm (IV–VI) | Lentigos, melasma, café-au-lait |
| Picosecond laser | 3–6 | Minimal–mild | Lower than QS nanosecond | Recalcitrant melasma, lentigos |
| Fractional non-ablative | 3–5 | 2–5 days | Moderate (IV–VI) | Diffuse pigmentation, texture |
| IPL | 3–5 | Minimal | High (IV–VI) — use with caution | Solar lentigos (Fitzpatrick I–III) |
| Microneedling | 3–6 | 1–3 days | Low–moderate | PIH, diffuse pigmentation |
| Microdermabrasion | 6–10 | None | Low | Superficial pigmentation, texture |
Oral and adjuvant therapies: when are systemic options considered?
Systemic treatments are almost always adjunctive rather than standalone solutions. They are considered when topical therapy and procedures have not achieved adequate control, or when the pigmentation pattern (particularly widespread or hormonally driven melasma) suggests a systemic component.
Oral tranexamic acid has the strongest evidence base among systemic options for melasma. It works by inhibiting the plasminogen-keratinocyte interaction that stimulates melanocyte activity, reducing UV-driven pigment production from within. Global consensus supports its use as an adjuvant to topical therapy and procedures in melasma, with evidence of benefit in combination regimes. It is prescribed at low doses (typically 250 mg twice daily) and requires clinical supervision. Contraindications include a personal or family history of thromboembolic events, pregnancy, and concurrent use of hormonal contraceptives in some clinical contexts. Baseline assessment and monitoring are standard practice.
Oral antioxidants and supplements (including oral vitamin C, polypodium leucotomos extract, and oral glutathione) are sometimes used alongside topical regimes. The evidence for these is less robust than for oral tranexamic acid; most studies are small or short-term. They are generally considered low-risk adjuncts rather than primary treatments, and their use should be discussed with a clinician.
Oral cysteamine is an emerging option with some early clinical data, though it is not yet widely available in standard UK clinical practice and remains largely investigational.
The key principle with systemic therapies is that they work best as part of a structured, clinician-supervised multimodal plan. Stopping a systemic agent without a maintenance topical and photoprotection strategy in place typically results in relapse, particularly with melasma.
What emerging therapies are on the horizon for pigmentation?
Research into novel delivery systems and biological treatments is advancing quickly, though most options in this category remain investigational or are available only through private clinics and specialist centres in the UK.
Nanocarrier and liposomal delivery systems encapsulate established actives (such as kojic acid, vitamin C, or retinoids) in lipid-based particles that penetrate the stratum corneum more efficiently than conventional formulations. Early clinical data is promising, particularly for improving the bioavailability of unstable actives like vitamin C. These are not yet widely available as licensed products in the UK, though some compounding pharmacies and specialist clinics offer bespoke formulations.
Microneedle-assisted delivery uses dissolvable or hollow microneedle patches to deposit actives directly into the dermis, bypassing the epidermal barrier. This approach is in active clinical investigation for melasma and PIH, with early results suggesting improved efficacy over topical application alone.
Platelet-rich plasma (PRP) is prepared from the patient’s own blood and injected or applied topically post-microneedling to deliver growth factors that modulate melanocyte activity and support dermal remodelling. Evidence from the Wiley review suggests PRP combined with microneedling is promising, though study quality and protocol consistency vary. PRP is available at private aesthetic clinics in the UK, including through The M-ethod Skin.
Polynucleotides (PDRN/PN) are DNA-derived biostimulators that reduce inflammation, support tissue repair, and may modulate melanocyte activity. They are gaining traction in UK aesthetic medicine as injectables for skin quality and pigmentation, though large-scale randomised controlled trial data specifically for hyperpigmentation is still limited.
Exosome therapy and stem cell-derived conditioned media represent the frontier of pigmentation research. Both are investigational in the UK context; long-term safety data is not yet available, and they are not part of standard clinical practice.
For most people in the UK, the realistic access route to emerging therapies is through a private specialist clinic offering PRP or polynucleotides, or through participation in a clinical trial for nanocarrier or microneedle-based treatments. Timelines for these approaches reaching routine NHS or standard private practice are difficult to predict, and anyone considering them should ask specifically about the evidence base and any known safety unknowns.
How do you match a treatment to your skin type and condition?
Choosing the right therapy starts with an accurate diagnosis. Melasma, solar lentigos, PIH, and drug-induced pigmentation each have different drivers, depths, and responses to treatment. Applying an aggressive laser to active inflammatory pigmentation, for example, can worsen the condition rather than improve it. Medscape’s global guideline is explicit: for conditions such as lichen planus pigmentosus and Riehl’s melanosis, topical calcineurin inhibitors and anti-inflammatory strategies should come before any laser or IPL intervention.
Fitzpatrick skin type and PIH risk
Fitzpatrick types IV–VI carry a higher baseline risk of post-inflammatory hyperpigmentation following any procedure that causes inflammation. For these skin types, clinicians prefer conservative, low-fluence, non-ablative, and topical-first strategies. Safer first-line choices include azelaic acid, niacinamide, topical tranexamic acid, and low-fluence Q-switched Nd:YAG at 1064 nm. Readers with deeper complexions will find specific protocol guidance in our article on skincare for deeper skin tones.
A practical decision checklist before starting treatment
Work through these questions before trying an OTC product or booking a procedure:
- Has the pigmentation been diagnosed? Confirm the type (melasma, PIH, solar lentigo, other) before selecting a treatment, ideally with a clinician’s input.
- What is your Fitzpatrick skin type? Higher types (IV–VI) need a more conservative approach and specialist oversight for any procedural option.
- Is there active inflammation or an active skin condition? Eczema, psoriasis, lichen planus pigmentosus, or active acne are contraindications to most procedural treatments until controlled.
- Are you pregnant or breastfeeding? Many actives (retinoids, hydroquinone, kojic acid) and all procedural treatments require medical clearance or avoidance. Azelaic acid at prescription strength and some topical vitamin C formulations are among the few options with a reasonable safety profile in pregnancy. See our pregnancy-safe pigmentation guide for detailed guidance.
- What is your recent sun exposure history? Procedures should not be performed on recently sun-exposed or tanned skin; a minimum of 2–4 weeks of strict sun avoidance and SPF use is standard pre-procedure preparation.
- What medications are you taking? Photosensitising drugs (certain antibiotics, retinoids, NSAIDs) increase the risk of adverse reactions to light-based treatments.
- What is your realistic maintenance commitment? Pigmentation management is ongoing. If you cannot commit to daily SPF and a maintenance topical, procedural results will be short-lived.
- Have you had a patch test? For any new topical active or procedural treatment, patch-testing at least 48 hours in advance is advisable.
Contraindications summary
Active inflammatory dermatoses, recent sun exposure, pregnancy, a history of keloid scarring (for microneedling), and photosensitising medications are the most common contraindications across procedural treatments. For topical agents, the main contraindications are pregnancy (retinoids, hydroquinone), known sensitisation (kojic acid, fragranced formulations), and active open wounds or broken skin.
Realistic treatment plans for common pigmentation conditions
No two pigmentation cases are identical, but the following protocols reflect how clinicians typically structure care for the three most common presentations. All three assume daily SPF 50+ as a non-negotiable foundation throughout.
Solar lentigos (sunspots)
Solar lentigos are discrete, well-defined epidermal lesions driven by cumulative UV exposure. They respond well to targeted procedural treatment.
Phase 1 (weeks 1–4): Introduce a topical tyrosinase inhibitor (vitamin C serum or niacinamide) and daily SPF 50+. This primes the skin and reduces background pigmentation before any procedure.
Phase 2 (weeks 4–16): Q-switched Nd:YAG or picosecond laser, typically 2–4 sessions spaced 4–6 weeks apart, or a series of superficial glycolic acid peels (4–6 sessions). Most people see significant clearance within this window.
Maintenance: Annual or biannual review; topical vitamin C and SPF year-round. New lesions may develop with ongoing sun exposure, so photoprotection remains the primary prevention strategy.
Melasma
Melasma is a chronic, relapsing condition with a strong hormonal and UV component. It requires a long-term management mindset rather than a one-off treatment.
Phase 1 (weeks 1–8): Prescription-strength topical combination (hydroquinone 4% or azelaic acid 20% with a retinoid and SPF 50+). Oral tranexamic acid may be added under clinical supervision for moderate to severe cases.
Phase 2 (weeks 8–20): Low-fluence Q-switched Nd:YAG or picosecond laser (3–6 sessions), or a series of superficial chemical peels, alongside continued topical maintenance. For evidence-based melasma treatment strategies, the melasma treatment guide offers a useful broader perspective.
Maintenance: Ongoing topical tranexamic acid or niacinamide, strict SPF, and seasonal review with a clinician. Relapse is common without maintenance; this is a management condition, not a curable one.
Post-inflammatory hyperpigmentation (PIH)
PIH follows skin injury or inflammation (acne, eczema, trauma). The primary driver must be controlled before pigmentation treatment begins.
Phase 1 (weeks 1–6): Control the underlying cause (acne treatment, eczema management). Introduce azelaic acid or niacinamide alongside SPF. Avoid any procedural treatment while inflammation is active.
Phase 2 (weeks 6–20): Add topical tranexamic acid or vitamin C. If improvement plateaus, a series of superficial salicylic acid peels (4–6 sessions) or microneedling (3–4 sessions) can accelerate clearance. Topical therapy is first-line for PIH; procedural options are second-line and require caution, particularly in Fitzpatrick types IV–VI.
Maintenance: Continue topical actives and SPF. PIH from recurrent acne or eczema will recur unless the underlying condition is managed consistently.
When should you see a dermatologist or skin specialist?
OTC topical therapy is a reasonable starting point for mild, stable pigmentation in fair to medium skin tones. There are clear situations, however, where self-management is not appropriate and specialist assessment is the right call.
Seek specialist review if:
- A pigmented lesion is changing in size, shape, or colour, or has irregular borders. This requires urgent dermatological assessment to rule out melanoma before any cosmetic treatment is considered.
- OTC therapy has been used consistently for 12 weeks without visible improvement.
- Pigmentation is widespread, rapidly spreading, or associated with systemic symptoms.
- You have Fitzpatrick type IV–VI skin and are considering any procedural treatment.
- Pigmentation developed during pregnancy or is associated with hormonal changes (oral contraceptive use, HRT).
- There is active inflammation, pain, or itch associated with the pigmented area.
- You have a history of keloid scarring, autoimmune skin conditions, or are on immunosuppressant medications.
A clinic assessment typically includes a detailed history (onset, triggers, medications, family history), visual examination under Wood’s lamp (which distinguishes epidermal from dermal pigmentation), and in some cases a skin biopsy or referral to a consultant dermatologist. You will receive a diagnosis, a tailored treatment plan, consent documentation, and baseline photographs for monitoring. Lasers and light-based devices require expert supervision, particularly in higher Fitzpatrick types, and a reputable clinic will always conduct a thorough assessment before recommending any procedural option.
This article provides general information about pigmentation treatments and is not a substitute for professional medical advice. Always confirm your diagnosis and treatment suitability with a qualified clinician or dermatologist.
Key takeaways
Daily photoprotection combined with a personalised, multimodal plan is the most evidence-backed approach to managing hyperpigmentation, and no single treatment offers a permanent cure for conditions such as melasma.
| Point | Details |
|---|---|
| Photoprotection is non-negotiable | Daily SPF 50+ is the foundation of every treatment plan; without it, all other therapies show limited or temporary results. |
| Topical agents are first-line | Tyrosinase inhibitors (azelaic acid, niacinamide, tranexamic acid) are the safest starting point, especially for Fitzpatrick types IV–VI. |
| Procedures need skin priming | Prime with topical actives for at least 4 weeks before any chemical peel, laser, or microneedling session to reduce PIH risk. |
| Multimodal plans outperform monotherapy | Combining topical and procedural approaches consistently produces superior outcomes compared with any single treatment. |
| Them-ethod offers clinical oversight | Them-ethod provides prescription-strength topicals, virtual skin consultations, and in-clinic procedures in London, including Obagi protocols and SkinPen microneedling. |
The case for patience over perfection in pigmentation care
There is a tendency in skincare culture to treat pigmentation as a problem to be solved quickly, ideally with one dramatic procedure. The clinical reality is more nuanced, and understanding that nuance is what separates people who get lasting results from those who cycle through treatments without progress.
What strikes me most about the evidence is how consistently it points to the same conclusion: the skin microenvironment matters as much as the melanocyte. Targeting vascular components, inflammatory mediators, and fibroblast activity alongside melanin synthesis produces more durable outcomes than melanocyte-directed therapy alone. This is why a well-formulated topical routine, maintained consistently, often outperforms a single aggressive procedure in the long run, particularly for melasma.
The Fitzpatrick safety question is also underappreciated. People with deeper skin tones are frequently offered the same procedural menu as those with fair skin, sometimes with inadequate priming or patch-testing. The result is paradoxical PIH that is harder to treat than the original pigmentation. A conservative, topical-first approach is not a compromise for higher Fitzpatrick types; it is the clinically correct starting point.
Realistic expectations matter too. Melasma is a chronic condition. Solar lentigos can clear beautifully with a targeted laser, but new ones will form without rigorous photoprotection. PIH from recurrent acne will return if the acne is not controlled. The most effective pigmentation plan is one you can sustain, not one that promises the fastest result.
At Them-ethod, we see this play out in practice. The clients who achieve the most consistent improvement are those who commit to the foundational routine, work with a clinician to select the right procedural option for their skin type, and treat maintenance as part of the plan rather than an afterthought.
How Them-ethod can support your pigmentation plan
Them-ethod brings together prescription-strength topicals, clinical-grade procedures, and expert consultation in one place, so you are not piecing together a plan from multiple sources without clinical oversight. As a UK-based Obagi Ambassador Clinic, we stock and prescribe the full Obagi pigmentation range, including prescription-strength formulations not available over the counter. Our virtual skin consultations connect you with expert clinicians who can assess your pigmentation type, Fitzpatrick skin type, and treatment history before recommending a personalised protocol.
For those in London, our in-clinic services include FDA-approved SkinPen microneedling, polynucleotide injectables, and Profhilo, all delivered with a structured pre- and post-treatment topical plan. We also carry a curated selection of cosmeceutical products, including the NEOSTRATA collection, which is well suited to pigmentation maintenance routines. If you are ready to move beyond OTC options, book a virtual consultation with our clinical team to receive a tailored pigmentation treatment plan with the right level of clinical support behind it.
Useful sources and further reading
The following sources informed this article and are recommended for further reading. Clinical consensus documents and peer-reviewed reviews are prioritised over single trials.
- Melanin hyperpigmentation disorders, management: global 2025 guideline summary (Medscape) — international clinical consensus; highest-level guidance on multimodal management algorithms by disorder and skin type.
- Management of hyperpigmentation: current treatments and emerging therapies (Wiley/Pigment Cell & Melanoma Research) — peer-reviewed clinical review covering topical agents, procedural options, and emerging therapies with evidence grading.
- Multimodality management of skin hyperpigmentation (Springer Nature) — clinical evaluation of combined laser and topical approaches versus monotherapy.
- Demystifying hyperpigmentation: causes, types, and effective treatments (Harvard Health) — accessible, evidence-based overview of photoprotection as the foundational treatment requirement.
- PMC: Hyperpigmentation review (PubMed Central) — peer-reviewed review article; useful background on mechanisms and treatment categories.
- British Association of Dermatologists (BAD) — UK clinical guidance and patient information on skin conditions including pigmentation disorders.
